Frontiers in Oncology | Pharmacology of Anti-Cancer Drugs

Systematic Review

Published on 08 Jan 2025

Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models

in Pharmacology of Anti-Cancer Drugs

Marcelo Simonsen
Rossana Verónica Mendoza López
Simone Maistro
Lucas Takeshi Ikeoka
Glaucia Fernanda de Lima Pereira
Ademar Benévolo Lugão
José Carlos Sadalla
Maria Lúcia Hirata Katayama
Maria Aparecida Azevedo Koike Folgueira

Frontiers in Oncology

doi 10.3389/fonc.2024.1487376

809 views

Review

Published on 07 Jan 2025

Selenium in cancer management: exploring the therapeutic potential

in Pharmacology of Anti-Cancer Drugs

Lingwen He
Lu Zhang
Yulong Peng
Zhijun He

Frontiers in Oncology

doi 10.3389/fonc.2024.1490740

1,683 views

Case Report

Published on 24 Dec 2024

Case report: Eczematous adverse drug reaction after selpercatinib treatment

in Pharmacology of Anti-Cancer Drugs

Bingrun Li
Peng Cao
Wenjing Xu
Litao Zhang

Frontiers in Oncology

doi 10.3389/fonc.2024.1475541

669 views
1 citation

Review

Published on 16 Dec 2024

Research progress of novel anti-tumor drug formulations

in Pharmacology of Anti-Cancer Drugs

Yan Liu
Qie Guo
YunYan Shi
MengNa Cui
FanBo Jing

Frontiers in Oncology

doi 10.3389/fonc.2024.1507958

951 views

Case Report

Published on 13 Dec 2024

Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review

in Pharmacology of Anti-Cancer Drugs

Huang Chen
Menglan Zhang
Liyan Bai
Yun Niu
Xiaowei Wang
Ruiying Jiang
Ye Wang
Qianqian Feng
Bei Wang
Tingli Dai

Frontiers in Oncology

doi 10.3389/fonc.2024.1453259

833 views

Review

Published on 11 Dec 2024

The antitumor mechanisms of glabridin and drug delivery strategies for enhancing its bioavailability

in Pharmacology of Anti-Cancer Drugs

Chong Li
Yu Wang
Wenjing Zhang
Xiaoman Yang
Yufang Wang
Guanqun Hou
Dongli Wang
Bingbing Han
Yimin Zhang

Frontiers in Oncology

doi 10.3389/fonc.2024.1506588

1,261 views

Correction

Published on 06 Dec 2024

Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells

in Pharmacology of Anti-Cancer Drugs

Graziana Digiacomo
Claudia Fumarola
Silvia La Monica
Mara Bonelli
Andrea Cavazzoni
Maricla Galetti
Rita Terenziani
Kamal Eltayeb
Francesco Volta
Silvia Zoppi

Frontiers in Oncology

doi 10.3389/fonc.2024.1532291

434 views

Editorial

Published on 06 Dec 2024

Editorial: Photodynamic therapy: challenges and innovations for treating cancer

in Pharmacology of Anti-Cancer Drugs

Newton Soares da Silva
Juliana Ferreira-Strixino
Cristina Pacheco-Soares

Frontiers in Oncology

doi 10.3389/fonc.2024.1526550

401 views

Original Research

Published on 05 Dec 2024

Pembrolizumab versus sintilimab in patients with advanced NSCLC: a retrospective multicenter study with propensity-score matching analysis

in Pharmacology of Anti-Cancer Drugs

Zhengzheng Xia
Juan Hong
Xiangyang Yu
Yuhua Ran
Huali Xie
Ziyuan Zhou
Jing Zuo
Tujia Chen
Jun Meng
Jun Yang

Frontiers in Oncology

doi 10.3389/fonc.2024.1422039

846 views

Original Research

Published on 05 Dec 2024

Cutaneous adverse events due to checkpoint inhibitors – a retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022

in Pharmacology of Anti-Cancer Drugs

Clara Furrer-Matcau
Chloé Sieber
Dirk Lehnick
Christoph Urs Brand
Balthasar Hug

Frontiers in Oncology

doi 10.3389/fonc.2024.1485594

830 views

Correction

Published on 03 Dec 2024

Corrigendum: Bruceine H mediates EGFR-TKI drug persistence in NSCLC by Notch3-dependent β-catenin activating FOXO3a signaling

in Pharmacology of Anti-Cancer Drugs

Jiahui Wu
Xiao He
Ziwei Xiong
Lingyu Shi
Daofeng Chen
Yulin Feng
Quan Wen

Frontiers in Oncology

doi 10.3389/fonc.2024.1515205

465 views

Editorial

Published on 02 Dec 2024

Editorial: DNA methylation in cancer therapy: therapeutic targets and molecular mechanism

in Pharmacology of Anti-Cancer Drugs

Guoyi Yan
Shaofeng Duan
Jinyang Cai

Frontiers in Oncology

doi 10.3389/fonc.2024.1508214

478 views

Correction

Published on 27 Nov 2024

Corrigendum: Chamaejasmin B decreases malignant characteristics of mouse melanoma B16F0 and B16F10 cells

in Pharmacology of Anti-Cancer Drugs

Lingling Si
Xinyan Yan
Yan Wang
Boxue Ren
Huanhuan Ren
Yangfang Ding
Qiusheng Zheng
Defang Li
Ying Liu

Frontiers in Oncology

doi 10.3389/fonc.2024.1472829

371 views

Correction

Published on 25 Nov 2024

Corrigendum: Long non-coding RNA SNHG1 regulates the Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways via EZH2 to affect the proliferation, apoptosis, and autophagy of prostate cancer cell

in Pharmacology of Anti-Cancer Drugs

Junyi Chen
Fubo Wang
Huan Xu
Lingfan Xu
Dong Chen
Jialiang Wang
Sihuai Huang
Yiqun Wen
Longmin Fang

Frontiers in Oncology

doi 10.3389/fonc.2024.1501882

851 views

Review

Published on 25 Nov 2024

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer

in Pharmacology of Anti-Cancer Drugs

Zhe Zhu
Wenjing Xuan
Chaohui Wang
Chancan Li

Frontiers in Oncology

doi 10.3389/fonc.2024.1481777

1,286 views

Case Report

Published on 20 Nov 2024

Case report: Tracing in parallel the salivary and gut microbiota profiles to assist Larotrectinib anticancer treatment for NTRK fusion–positive glioblastoma

in Pharmacology of Anti-Cancer Drugs

Luigia Turco
Rosa Della Monica
Pasqualina Giordano
Mariella Cuomo
Manuele Biazzo
Baptiste Mateu
Raimondo Di Liello
Bruno Daniele
Nicola Normanno
Antonella De Luca

Frontiers in Oncology

doi 10.3389/fonc.2024.1458990

1,132 views